INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 12, 2018	Aug. 20, 2018	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Naltrexone Implant Formulation [Member] \| Australia from Trinity Compound Solutions [Member]
Cash paid for acquisition		$ 10,000
Aggregate purchase price, Shares		20,000
Aggregate purchase price, value		$ 236,000
Patent acquired	$ 15,200
Estimated useful lives	13 years
Patents [Member]
Amortization expense			$ 294	$ 295	$ 884	$ 884
Accumulated amortization			4,699		4,699
Impairment loss					141,480
Intellectual property, carrying value			0		0
Intellectual Property [Member]
Amortization expense			$ 0	$ 11,790	$ 0	$ 35,370
Estimated useful lives					5 years